Is CMPX or CTOR more profitable?

Compass Therapeutics' return on equity of -38.71% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -38.71% -34.72% Citius Oncology N/A -102.98% -43.49%

Does the media favor CMPX or CTOR?

In the previous week, Compass Therapeutics had 14 more articles in the media than Citius Oncology. MarketBeat recorded 15 mentions for Compass Therapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Compass Therapeutics' score of -0.32 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CTOR or QTTB?

Q32 Bio has a consensus price target of $31.00, indicating a potential upside of 224.27%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts plainly believe Q32 Bio is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is CTOR or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Q32 Bio N/A 50.17% 29.49%

Does the media prefer CTOR or QTTB?

In the previous week, Q32 Bio had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Q32 Bio and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Q32 Bio's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Q32 Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CTOR or SION?

Sionna Therapeutics has a consensus price target of $42.33, suggesting a potential upside of 668.30%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sionna Therapeutics 1 Sell rating(s) 11 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CTOR or SION more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Sionna Therapeutics N/A -32.94% -31.08%

Does the media prefer CTOR or SION?

In the previous week, Sionna Therapeutics had 9 more articles in the media than Citius Oncology. MarketBeat recorded 10 mentions for Sionna Therapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Sionna Therapeutics' score of 0.14 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CTOR or AGEN?

Agenus has a consensus target price of $26.33, indicating a potential upside of 213.49%. Given Agenus' stronger consensus rating and higher probable upside, analysts clearly believe Agenus is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Agenus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is CTOR or AGEN more profitable?

Agenus has a net margin of 69.33% compared to Citius Oncology's net margin of 0.00%. Agenus' return on equity of -47.68% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -102.98% -43.49% Agenus 69.33% -47.68% 57.73%

Does the media refer more to CTOR or AGEN?

In the previous week, Agenus had 6 more articles in the media than Citius Oncology. MarketBeat recorded 7 mentions for Agenus and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Agenus' score of 0.47 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SABS or CTOR more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -6.74% -6.06% Citius Oncology N/A -102.98% -43.49%

Does the media favor SABS or CTOR?

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat SAB Biotherapeutics' score of 0.00 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Citius Oncology (CTOR) Competitors

$1.01 -0.06 (-5.61%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.03 +0.02 (+1.98%)

As of 08:14 AM Eastern

Compare

CTOR vs. CMPX, QTTB, SION, AGEN, and SABS

Should you buy Citius Oncology stock or one of its competitors? Citius Oncology's main competitors and comparable companies include Compass Therapeutics (CMPX), Q32 Bio (QTTB), Sionna Therapeutics (SION), Agenus (AGEN), and SAB Biotherapeutics (SABS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Citius Oncology compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Compass Therapeutics currently has a consensus price target of $10.21, indicating a potential upside of 773.02%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Compass Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Compass Therapeutics' return on equity of -38.71% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Citius Oncology	N/A	-102.98%	-43.49%

Citius Oncology has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	247.89	-$66.49M	-$0.40	N/A
Citius Oncology	$7.11M	13.22	-$24.76M	-$0.47	N/A

Compass Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, suggesting that its stock price is 252% more volatile than the broader market.

In the previous week, Compass Therapeutics had 14 more articles in the media than Citius Oncology. MarketBeat recorded 15 mentions for Compass Therapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Compass Therapeutics' score of -0.32 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Citius Oncology on 10 of the 16 factors compared between the two stocks.

How does Citius Oncology compare to Q32 Bio?

Citius Oncology (NASDAQ:CTOR) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Q32 Bio has a consensus price target of $31.00, indicating a potential upside of 224.27%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts plainly believe Q32 Bio is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Citius Oncology has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

In the previous week, Q32 Bio had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Q32 Bio and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Q32 Bio's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Q32 Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$7.11M	13.22	-$24.76M	-$0.47	N/A
Q32 Bio	$53.74M	5.30	$29.82M	$3.00	3.19

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 34.5% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Q32 Bio's return on equity of 50.17% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Q32 Bio	N/A	50.17%	29.49%

Summary

Q32 Bio beats Citius Oncology on 12 of the 16 factors compared between the two stocks.

How does Citius Oncology compare to Sionna Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Citius Oncology has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$7.11M	13.22	-$24.76M	-$0.47	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Sionna Therapeutics has a consensus price target of $42.33, suggesting a potential upside of 668.30%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sionna Therapeutics' return on equity of -32.94% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Sionna Therapeutics	N/A	-32.94%	-31.08%

70.5% of Citius Oncology shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sionna Therapeutics had 9 more articles in the media than Citius Oncology. MarketBeat recorded 10 mentions for Sionna Therapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Sionna Therapeutics' score of 0.14 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Citius Oncology has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Summary

Citius Oncology beats Sionna Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Agenus?

Citius Oncology (NASDAQ:CTOR) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 6.5% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Agenus has a net margin of 69.33% compared to Citius Oncology's net margin of 0.00%. Agenus' return on equity of -47.68% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-102.98%	-43.49%
Agenus	69.33%	-47.68%	57.73%

Citius Oncology has a beta of 3.52, indicating that its stock price is 252% more volatile than the broader market. Comparatively, Agenus has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

In the previous week, Agenus had 6 more articles in the media than Citius Oncology. MarketBeat recorded 7 mentions for Agenus and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat Agenus' score of 0.47 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agenus has a consensus target price of $26.33, indicating a potential upside of 213.49%. Given Agenus' stronger consensus rating and higher probable upside, analysts clearly believe Agenus is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Agenus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Agenus has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	$7.11M	13.22	-$24.76M	-$0.47	N/A
Agenus	$114.20M	3.32	$120K	$2.58	3.26

Summary

Agenus beats Citius Oncology on 11 of the 16 factors compared between the two stocks.

How does Citius Oncology compare to SAB Biotherapeutics?

SAB Biotherapeutics (NASDAQ:SABS) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

SAB Biotherapeutics has higher earnings, but lower revenue than Citius Oncology. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$1.32M	233.68	$13.27M	-$1.30	N/A
Citius Oncology	$7.11M	13.22	-$24.76M	-$0.47	N/A

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 9.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SAB Biotherapeutics' return on equity of -6.74% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-6.74%	-6.06%
Citius Oncology	N/A	-102.98%	-43.49%

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.67 beat SAB Biotherapeutics' score of 0.00 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SAB Biotherapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 253.98%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market.

Summary

SAB Biotherapeutics beats Citius Oncology on 8 of the 15 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$99.49M	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-2.15	13.88	274.10	25.70
Price / Sales	13.22	1,437.48	672.61	90.85
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.87	15.45	10.48	6.32
Net Income	-$24.76M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-0.98%	-1.68%	-0.68%	0.17%
1 Month Performance	34.67%	-6.15%	-3.18%	-3.27%
1 Year Performance	-44.20%	30.67%	15.13%	5.58%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	0.364 of 5 stars	$1.01 -5.6%	N/A	-44.2%	$99.49M	$7.11M	N/A	N/A	News Coverage Positive News
CMPX Compass Therapeutics	2.2918 of 5 stars	$1.83 -1.4%	$11.77 +544.9%	-65.4%	$328.66M	$850K	N/A	39	Trending News Analyst Downgrade
QTTB Q32 Bio	3.151 of 5 stars	$11.01 -1.4%	$31.00 +181.5%	+428.2%	$328.36M	$53.74M	3.68	22
SION Sionna Therapeutics	3.1831 of 5 stars	$7.24 +5.2%	$42.33 +485.1%	-79.4%	$327.32M	N/A	N/A	59	Insider Trade
AGEN Agenus	2.9716 of 5 stars	$7.11 -0.7%	$19.50 +174.3%	+89.2%	$321.00M	$114.20M	2.76	81

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. CMPX, QTTB, SION, AGEN, and SABS

How does Citius Oncology compare to Compass Therapeutics?

Summary

How does Citius Oncology compare to Q32 Bio?

Summary

How does Citius Oncology compare to Sionna Therapeutics?

Summary

How does Citius Oncology compare to Agenus?

Summary

How does Citius Oncology compare to SAB Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. CMPX, QTTB, SION, AGEN, and SABS

How does Citius Oncology compare to Compass Therapeutics?

Do institutionals & insiders believe in CMPX or CTOR?

Do analysts recommend CMPX or CTOR?

Is CMPX or CTOR more profitable?

Which has better valuation & earnings, CMPX or CTOR?

Which has more risk & volatility, CMPX or CTOR?

Does the media favor CMPX or CTOR?

Summary

How does Citius Oncology compare to Q32 Bio?

Do analysts prefer CTOR or QTTB?

Which has more risk & volatility, CTOR or QTTB?

Does the media prefer CTOR or QTTB?

Which has stronger valuation & earnings, CTOR or QTTB?

Do insiders and institutionals have more ownership in CTOR or QTTB?

Is CTOR or QTTB more profitable?

Summary

How does Citius Oncology compare to Sionna Therapeutics?

Which has preferable valuation & earnings, CTOR or SION?

Do analysts prefer CTOR or SION?

Is CTOR or SION more profitable?

Do insiders & institutionals hold more shares of CTOR or SION?

Does the media prefer CTOR or SION?

Which has more volatility and risk, CTOR or SION?

Summary

How does Citius Oncology compare to Agenus?

Do insiders & institutionals believe in CTOR or AGEN?

Is CTOR or AGEN more profitable?

Which has more volatility and risk, CTOR or AGEN?

Does the media refer more to CTOR or AGEN?

Do analysts prefer CTOR or AGEN?

Which has stronger valuation & earnings, CTOR or AGEN?

Summary

How does Citius Oncology compare to SAB Biotherapeutics?

Which has stronger earnings & valuation, SABS or CTOR?

Do institutionals & insiders have more ownership in SABS or CTOR?

Is SABS or CTOR more profitable?

Does the media favor SABS or CTOR?

Do analysts prefer SABS or CTOR?

Which has more volatility & risk, SABS or CTOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools